July 11, 2018

New funding for the Canadian Cancer Clinical Trials Network will help more cancer patients access clinical trials

Toronto (July 11, 2018) – The Ontario Institute for Cancer Research (OICR) and the Canadian Partnership Against Cancer (the Partnership) today announced renewed funding for the Canadian Cancer Clinical Trials Network (3CTN). The funding will ensure Canada remains a world leader in academic cancer clinical trials, help to increase opportunities for patients to receive promising new treatments and continue to improve outcomes for cancer patients through research.

Continue reading – New funding for the Canadian Cancer Clinical Trials Network will help more cancer patients access clinical trials

July 10, 2018

Targeting epigenetic proteins could help prevent breast cancer

Dr. Julie Livingstone

Researchers further clarify the role of epigenetic proteins in the development of breast cancer, and discover that inhibiting these proteins could prevent the disease in women at high risk.

Continue reading – Targeting epigenetic proteins could help prevent breast cancer

July 10, 2018

Researchers find early indicators of leukemia in genomes up to 10 years before symptoms surfaced

Immature blood cells in leukemia

Acute myeloid leukemia (AML) progresses quickly and requires treatment soon after diagnosis, but the disease begins long before becoming symptomatic. Early indicators of AML were thought to be indistinguishable from healthy aging. But now, an international group of researchers led in part by Dr. Sagi Abelson, a postdoctoral fellow in the lab of Dr. John Dick at the Princess Margaret Cancer Centre, has discovered distinctive traces of AML in patients up to 10 years before they were diagnosed with the disease.

Continue reading – Researchers find early indicators of leukemia in genomes up to 10 years before symptoms surfaced

July 9, 2018

New institute to make chronic disease prevention across Canada BETTER

Dr. Eva Grunfeld

The BETTER program has been awarded almost $3 million to train primary care providers as prevention experts across Canada

As the number of Canadians at risk of cancer and other chronic diseases continues to grow, so does the need for health professionals to deliver effective disease prevention and screening recommendations.

Continue reading – New institute to make chronic disease prevention across Canada BETTER

June 27, 2018

Healthcare Software Start-Up Ziliomics Financed by FACIT

World-leading genomics cloud computing group builds clinical tool for cancer care in Ontario

TORONTO, ON (June 27, 2018) – Ziliomics Inc., a start-up created by FACIT, received seed financing from the Prospects Oncology Fund. Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer. Together with FACIT’s interim executive management model, the capital advances the development of Heliotrope, Ziliomics’ lead software product, and positions the company for corporate partnerships and additional financing. Financing terms were not disclosed.

Continue reading – Healthcare Software Start-Up Ziliomics Financed by FACIT

June 19, 2018

More than 300,000 Canadians enrol in multi-decade research initiative to monitor disease trends

CPTP Leaders in OICR Data Centre

From left, Dr. John McLaughlin, executive director of CPTP, Cindy Morton, chief executive officer of the Canadian Partnership Against Cancer, and Dr. Philip Awadalla, national scientific director of CPTP

Over the past 10 years, more than 300,000 Canadians have volunteered to be part of the Canadian Partnership for Tomorrow Project (CPTP), a research platform that tracks the development of cancers and chronic diseases in the population over several decades to better understand risk factors.

Researchers from across Canada and the University of Toronto published a manuscript in the Canadian Medical Association Journal last week, marking a culmination of effort from hundreds of Canadian researchers to build the project with support from multiple national and provincial funders.

Continue reading – More than 300,000 Canadians enrol in multi-decade research initiative to monitor disease trends

June 14, 2018

New OICR President and Scientific Director comments on breakthroughs in breast cancer T-cell immunotherapy

Dr. Laszlo Radvanyi

For the first time, a patient’s late-stage breast cancer has been successfully treated with T-cell immunotherapy. This cutting-edge approach, which is currently in clinical trials in the U.S., modified the patient’s naturally-occurring immune cells to fight her tumours that had spread throughout her body. The patient has been cancer free for the past two years and her remarkable tumour regression represents the potential impact of this new immunotherapeutic approach.

Continue reading – New OICR President and Scientific Director comments on breakthroughs in breast cancer T-cell immunotherapy

June 13, 2018

Viral protein identified as one of the main drivers of virus-induced stomach cancers

The Epstein Barr virus in false Colour

Some common pathogens, like the Epstein-Barr virus (EBV), can turn healthy cells into cancer cells, but it is not well understood how they do so. Better understanding how such pathogens work allows researchers to find new ways to target the pathogen’s disease-causing mechanisms and ultimately find new treatments for certain virus-induced cancers.

Dr. Ivan Borozan, from Dr. Vincent Ferretti’s Lab at OICR, and Prof. Lori Frappier at the University of Toronto are working together to better understand EBV and how it triggers the transformation of normal cells to cancerous cells, also known as oncogenesis. Together, they have identified that a key protein expressed by EBV, BKRF4, is one of the likely drivers behind EBV-induced stomach cancers.

Continue reading – Viral protein identified as one of the main drivers of virus-induced stomach cancers

June 13, 2018

FACIT Appoints Biotech Veteran Dr. David O’Neill as President

Entrepreneur adds US oncology management experience to Ontario commercialization

David o'NeillTORONTO, ON (June 13, 2018) — The Board of Trustees announced the appointment of David O’Neill as the President of FACIT. Dr O’Neill joined FACIT in 2013 as Vice President, Business Development, bringing cancer drug development expertise as well as an extensive business network in pharma and biotech. As Acting President for the last year, he has elevated the profile of the organization and enabled FACIT to continue to deliver critical commercialization financing to innovative start-ups in the growing Ontario market.

Continue reading – FACIT Appoints Biotech Veteran Dr. David O’Neill as President

June 4, 2018

New guidelines for HER2 testing in breast cancer

An image of the HER2 protein.

Current HER2 tests help predict which breast cancer patients will respond to HER2-targeted therapies, but sometimes these tests provide unclear results. An Expert Panel of pathologists and cancer researchers, including Dr. John Bartlett from OICR, recently published revised clinical practice guidelines for HER2 testing in breast cancer to help improve clarity of HER2 test results.

Continue reading – New guidelines for HER2 testing in breast cancer

May 23, 2018

OICR’s Cancer Genome Collaboratory wins 2018 OpenStack Superuser award for contributions to the cancer research community

Vincent Ferretti's lab at work.

Based on popular vote and review by the Superuser Editorial Advisory Board, OICR’s Cancer Genome Collaboratory team has won the 2018 OpenStack Vancouver Summit Superuser Award. The Award recognizes OICR’s use of OpenStack, an open-source software platform for cloud computing, to enable cancer research worldwide. Previous winners of the Superuser Award include AT&T, CERN and Comcast.

“We’re proud to be recognized by the greater research community that we support,” Vincent Ferretti, Director and Senior Principal Investigator, Genome Informatics at OICR, says. “OpenStack has helped us contribute to the cancer research community in Ontario, across Canada and internationally.”

Continue reading – OICR’s Cancer Genome Collaboratory wins 2018 OpenStack Superuser award for contributions to the cancer research community

May 23, 2018

Bioinformatics.ca launches 2018 pan-Canadian annual workshop series to train big data talent

CBW Group

Researchers, specifically those studying cancer, require expertise to tackle increasingly complex, large datasets that are generated by rapidly developing sequencing technologies. Bioinformatics.ca has launched their 2018 Canadian Bioinformatics Workshops (CBW) series to train Canadian and international scientists on cutting-edge topics in bioinformatics – preparing them to harness the potential of big data.

Continue reading – Bioinformatics.ca launches 2018 pan-Canadian annual workshop series to train big data talent

Next Page »